Market Cap : 16.05 B | Enterprise Value : 13.37 B | PE Ratio : 16.98 | PB Ratio : 3.92 |
---|
NAS:INCY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:INCY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Incyte's average Accounts Receivable for the three months ended in Jun. 2022 was $623 Mil. Incyte's Revenue for the three months ended in Jun. 2022 was $911 Mil. Hence, Incyte's Days Sales Outstanding for the three months ended in Jun. 2022 was 62.34.
The historical rank and industry rank for Incyte's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Incyte's highest Days Sales Outstanding was 67.12. The lowest was 33.29. And the median was 50.71.
INCY's Days Sales Outstanding is ranked better thanIncyte's Days Sales Outstanding increased from Jun. 2021 (54.02) to Jun. 2022 (62.34).
The historical data trend for Incyte's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Incyte's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Incyte's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Incyte's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as
Days Sales Outstanding (A: Dec. 2021 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2020 ) | + | Accounts Receivable (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) | * | Days in Period |
= | ( (481.994 | + | 616.3) | / | 2 ) | / | 2986.267 | * | 365 |
= | 549.147 | / | 2986.267 | * | 365 | ||||
= | 67.12 |
Incyte's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:
Days Sales Outstanding (Q: Jun. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2022 ) | + | Accounts Receivable (A: Jun. 2022 )) | / | count ) | / | Revenue (A: Jun. 2022 ) | * | Days in Period |
= | ( (562.344 | + | 682.968) | / | 2 ) | / | 911.397 | * | 365 / 4 |
= | 622.656 | / | 911.397 | * | 365 / 4 | ||||
= | 62.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Incyte's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Tray Thomas | officer: Principal Accounting Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Brawley Otis W | director | 5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518 |
High Katherine A | director | 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 |
Harrigan Edmund | director | |
Morrissey Michael James | officer: EVP, Head of Tech. Operations | IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Dickinson Jonathan Elliott | officer: EVP, General Manager, Europe | CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803 |
Stamoulis Christiana | officer: EVP & Chief Financial Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139 |
Dhanak Dashyant | officer: EVP & Chief Scientific Officer | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Pasquale Maria E | officer: EVP & General Counsel | C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Fouse Jacqualyn A | director | C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108 |
Iyengar Vijay K | officer: EVP GPS, BD, & Licensing | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Stein Steven H | officer: EVP & Chief Medical Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Trower Paul | officer: VP, Finance & Prin Acc Officer | 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 |
Clancy Paul J | director | C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Bienaime Jean Jacques | director | 925 PAGE MILL ROAD PALO ALTO CA 94304 |
Other Sources
By Zacks 2021-12-02
By Zacks 2022-01-27
By tipranks.com 2022-02-08
By Zacks 2022-02-08
By tipranks.com 2022-02-11
By Zacks 2021-12-06
By tipranks.com 2022-03-27
By Zacks 2022-02-03
By tipranks.com 2022-02-09
By tipranks.com 2022-02-10
By Seekingalpha 2021-12-28
By Seekingalpha 2021-11-02
By Zacks 2022-01-17
By Zacks 2022-03-28
By Zacks 2022-03-10